non-cystic fibrosis bronchiectasis

News

FDA, Brensocatib and Cystic Fibrosis

Brensocatib Becomes First FDA-Approved Therapy for Bronchiectasis

Brensocatib (Brinsupri; Insmed) gains FDA approval as the first treatment for bronchiectasis, offering hope to patients with the chronic lung disease.

Healio · 4d

FDA approves brensocatib for non-cystic fibrosis bronchiectasis

PharmExec · 4d

FDA Approves Insmed’s Brinsupri as First Treatment for Non-Cystic Fibrosis Bronchiectasis

BioSpace3d

Insmed Wins Approval for First Bronchiectasis Drug and DPP1 Blocker

Insmed's Brinsupri is the first DPP1 inhibitor approved by the FDA and the first treatment for bronchiectasis to reach the ...

Monthly Prescribing Reference12y

Azithromycin Treats Non-Cystic Fibrosis Bronchiectasis

Conroy Wong, MB, ChB, from Middlemore Hospital in Auckland, New Zealand, and colleagues conducted a randomized trial involving patients with non-cystic fibrosis bronchiectasis. Participants, who ...

Stocktwits on MSN3d

HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week

H.C. Wainwright on Wednesday doubled its price target on Insmed (INSM) to $240 from $120 while keeping a ‘Buy’ rating on the ...

The Globe and Mail5mon

Non-Cystic Fibrosis Bronchiectasis Clinical Trials and Pipeline 2025 ...

Non-Cystic Fibrosis Bronchiectasis companies in the treatment market are NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutic, CSL Behring, Haisco Pharmaceutical, SolAeroMed ...

Pharmaceutical Technology4d

Fosun and Expedition make $645m licensing deal for respiratory drug

Fosun Pharma Industrial has entered a licence agreement to grant ex-China rights for its respiratory drug, XH-S004, to Expedition.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results